Edition:
United Kingdom

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.97USD
8:59pm GMT
Change (% chg)

$-0.01 (-1.11%)
Prev Close
$0.98
Open
$0.95
Day's High
$0.99
Day's Low
$0.90
Volume
73,522
Avg. Vol
139,192
52-wk High
$5.20
52-wk Low
$0.78

Select another date:

Wed, Feb 14 2018

BRIEF-Delmar Pharmaceuticals Q2 Loss Per Share $0.14

* DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage:

BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO

* Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer

BRIEF-DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6

* DelMar Pharmaceuticals Inc CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing Source text: (http://bit.ly/2kDnPBr) Further company coverage:

BRIEF-DelMar Pharmaceuticals announces $10 million registered direct offering

* Announces $10 million registered direct offering priced at-the-market

BRIEF-Delmar Pharmaceuticals receives IND allowance from FDA

* Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer Source text for Eikon: Further company coverage:

BRIEF-Delmar Pharmaceuticals initiates phase 2 clinical trial

* Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme

Select another date: